Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension - A randomised ABPM study

Journal of Human Hypertension

Volumn 17, Issue 8, 2003, Pages 569-575

  Neutel, J M ^a   Kolloch, R E ^b   Plouin, P F ^c   Meinicke, T W ^d   Schumacher, H ^d  

^a Orange County Heart Institute and Research Center   (United States)

^b Gilead Hospital   (Germany)

^c HÔPITAL BROUSSAIS   (France)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

ABPM; AT1 receptor antagonist; Combination therapy; Losartan hydrochlorothiazide; Telmisartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; PLACEBO; TELMISARTAN;

ADULT; ARTHRITIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRONCHITIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DUODENUM ULCER; ECZEMA; ESSENTIAL HYPERTENSION; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMIPARESIS; HOME ACCIDENT; HUMAN; LOW BACK PAIN; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; OPEN STUDY; PARALLEL DESIGN; PARESTHESIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SWEATING; SYSTOLIC BLOOD PRESSURE; UROLITHIASIS; VERTIGO;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; DIURETICS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; SODIUM CHLORIDE SYMPORTER INHIBITORS; TREATMENT OUTCOME;

EID: 0041589771     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001592     Document Type: Article

References (20)

1. Hansson L et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
2. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-2446.
3. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
4. Burt VL et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the Health Examination Surveys, 1960 to 1991. Hypertension 1995; 26: 60-69.
5. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: Is the 'rule of halves' still valid? J Hum Hypertens 1997; 11: 213-220.
6. Neutel JM, Smith DHG. Familial aspects of the hypertension syndrome. J Cardiovasc Risk 1997; 4: 243-249.
7. Neutel JM et al. Low dose combination therapy as first line treatment of mild-to-moderate hypertension: The efficacy and safety of bisoprolol/HCTZ versus amlodipine, enalapril, and placebo. Cardiovasc Rev Rep 1996; 71: 33-45.
8. Neutel JM, Smith DHG. Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998; 15: 206-217.
9. Neutel JM et al. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther 1999; 6: 161-166.
10. Mallion JM et al. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13: 657-664.
11. Lacourcière Y et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Press Monit 1998; 3: 295-302.
12. White WB et al. Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate and heart rate-blood pressure product. Am J Cardiol 1998; 81: 424-431.
13. Smith DHG et al. Prospective, Randomized, Open-label, Blinded Endpoint (PROBE) designed trials yield the same results as traditional double-blind, placebo-controlled trials with respect to ambulatory blood pressure measurements. J Hypertens 2002; submitted.
14. Cook NR et. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995; 155: 701-709.
15. Psaty BM et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: The cardiovascular health study. Arch Intern Med 2001; 161: 1183-1192.
16. Sharpe M, Jarvis B, Goa KL. Telmisartan: A review of its use in hypertension. Drugs 2001; 61: 1501-1529.
17. Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press 2001; 10 (Suppl 1): 6-11.
18. Neutel JM et al. Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements. Am Heart J 1990; 120: 166-171.
19. Neutel JM. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med 1993; 94: 181-187.
20. Neutel JM et al. Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications. Blood Press 2002; 11: 302-309.